A novel 3D polymeric tool for accurate screening of the performance of immunodiagnostic polymeric microneedles by Totti S et al.
A novel 3D polymeric tool for accurate screening of the performance of 
immunodiagnostic polymeric microneedles  
 
Stella Totti1, Keng Wooi Ng2, Guoping Lian1,3, Tao Chen1 and Eirini G. Velliou1 
 
1BioProcess and Biochemical Engineering group (BioProChem), Department of Chemical and Process 
Engineering, University of Surrey, Guildford,UK; 2 School of Pharmacy, University of Newcastle, Newcastle, 
UK; 3 Unilever R&D Colworth, Colworth Park, Sharnbrook, UK 
 
INTRODUCTION: Melanoma is the most lethal skin cancer, having a rapid increase of occurrence 
over the past 30 years1.To date, the most effective treatment for melanoma is the early diagnosis, which 
is followed by surgical resection. Therefore, in order to improve these disappointing statistical figures, 
it is essential to develop efficient diagnostic tools for rapid detection of the disease’s specific markers. 
Minimally invasive microneedles (MNs) are promising candidates, as they enable rapid and pain-free 
protein biomarker detection in situ. However, validating the developed microneedle (MN) systems 
remains a bottleneck. To date, the most commonly used systems for in vitro microneedle validation are 
either homogeneous solutions that contain the target antigen to be detected by the MNs or excised 
animal skin. Animal skin strikes many similarities with the human skin, however the animal skin 
properties, such as stiffness, elasticity, porosity, which vary between different patients cannot be easily 
tuned/ tailored 2. Furthermore, antigen solutions can be informative for a preliminary evaluation of the 
MN arrays, but they are not representative models of in vivo skin structure and biomarker concentration. 
Biomaterial based 3D structures can simulate important skin tissue features, such as stiffness, elasticity, 
porosity, structure, extracellular matrix presence that can vary between different patients, different skin 
types and with ageing. Moreover, they can provide a realistic structural environment for the penetration 
and action of MN.   Therefore, these biomaterial based 3D structures have great potential as screening 
tools for MN evaluation. The aim of this work was to validate the S100 expression, a marker that is 
upregulated in melanoma, on a microporous polymer based 3D melanoma model. S100 expression in 
the model was confirmed using a novel immunodiagnostic microneedle device. 
METHODS: 3D polymer (PU) based microporous scaffolds (5x5x2.5mm3) were developed using the 
Thermally Induced Phase Separation (TIPS) method, as described previously3. The porosity was 80% 
and the pore size 100-120 μm. Thereafter, the metastatic melanoma cell line A-375 was injected and 
cultured in those scaffolds for 5 weeks. Evaluation of cell distribution within the PU matrix was 
conducted with Scanning Electron Microscopy (SEM). Viable (live) cells were visualised in situ with 
confocal laser scanning microscopy (CLSM) of several sections of each scaffold. Furthermore, the 
detection of the S100 marker was carried out with PLA microneedles both on the 3D scaffold and for 
the cell culture supernatants. The PLA microneedle device was produced, surface modified and coated 
with the S100 antibody as previously described, followed by the detection of the antigen via 
immunoassay analysis on the microneedle surface4.  
RESULTS: The MN device was able to detect the S100 secretion from the melanoma cells in the 
scaffold after 35 days of a viable culture, producing a clear and visible detection signal similar to the 
one detected for the positive control samples. However, S100 gradients were not detected in the cell 
culture supernatants, suggesting that this versatile scaffolding tool can be an advantageous low cost 
animal free tool to be use as a surrogate for the in vitro evaluations of the MNs.  
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